Articles

The dual labelling period for some medicine ingredients is ending on 30 April 2025.

We are seeking applications from professionals with relevant expertise in medicine and science, and consumers with relevant expertise in consumer perspectives and issues.

We will be initiating targeted compliance reviews of selected listed medicines that are required to display a warning statement

The Prescription Medicines in Pregnancy database has now been updated to include the following new entries:

Listed medicine compliance review reports database March 2025 update

Your participation in this online activity will help us create a more user-friendly website that works better for everyone.

The updated plan emphasises solidifying our collaborative processes, aligning expectations with industry, and improving our communication strategies.

Following a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established.

From 1 March 2025, sponsors of vaping goods will be able to use a new online form of the sponsor notice.

We are updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI)

The TGA has released a literature review of certain active ingredients used in sunscreens.

Your feedback is essential to shaping a user-friendly website that works better for everyone.

Recall reforms program update and preview of the PRAC Version 1.0.

Find out about new requirements for labels of injectable electrolyte medicines and updates to guidance for medicine sponsors.

We have introduced new features to improve your experience using Guidance on our website.

TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).

The TGA is updating information for nitrosamine impurities in medicines including acceptable intakes (AI).

Following our Essential Principles presentations on 11-12 September 2024, we have collated questions asked into themes to simplify finding information of relevance to you.

From 28 October 2024, Telstra and Optus are switching off their 3G networks. Medical devices and products like personal medical alarms could be affected by these closures.

The Prescription Medicines in Pregnancy database has been updated to include new and amended entries.

The TGA is working with participating businesses to arrange the surrender of their vaping goods.

Two new quality standards, one for MDMA and another for psilocybine, have been published.

The TGA has been reviewing the safety and performance of spinal cord stimulator (SCS) devices.

A reminder about financial deadlines that are approaching for sponsors and manufacturers.

Some changes are rolling out soon to improve your experience using guidance on our website. We’re aiming to make our content clearer, more accessible and easier to navigate.